FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP
O 17 (1 E.III.E. 1 1 1	0. 0.17.11020	III DEITE IONE	O IIIII

OMB APPROVAL								
OMB Number: 3235-02								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Patel Sanj \underline{K}					2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [KNSA]					(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
	(F IIKSA PHA		3. Date of Earliest Transaction (Month/Day/Year) 09/02/2021						X Officer (give title below) Other (specify below) Chairman & CEO							
CLARENDON HOUSE 2 CHURCH STREET (Street)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
HAMILT	ON D	0	HM11)	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)									reison				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			е	action 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.)) 8)			Beneficia Owned Fe	s Ily ollowing	Form: I	m: Direct I or Indirect I nstr. 4) (7. Nature of ndirect Beneficial Ownership			
			Code V			Amoun	(A) o	r Price	Reported Transacti (Instr. 3 a	tion(s)			Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, Transact		saction Derivative E		Expiration Date (Month/Day/Year) Of De		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	JII(S)		
Share Option	\$12.97	09/02/2021		A		157,658		(1)	09/01/2031	Class A Common Shares	157,658	\$0	157,65	8	D	
Restricted Share Units	(2)	09/02/2021		A		26,276		(3)	(3)	Class A Common Shares	26,276	\$0	26,276	5	D	

Explanation of Responses:

- 1. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.
- $2. \ Each \ Restricted \ Share \ Unit \ represents \ a \ contingent \ right \ to \ receive \ one \ Class \ A \ Common \ Share \ of \ the \ Issuer.$
- 3. The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

/s/ Madelyn Zeylikman,

09/07/2021 Attorney-in-Fact for Sanj K

Patel

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.